- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06058078
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
A Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of RY_SW01cell Injection Therapy in Active Lupus Nephritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial is an exploratory study, including two stages: the dose-escalation phase (Phase I) and the dose-expansion phase (Phase II), as part of a multicenter clinical trial. The Phase I dose-escalation stage employs a dose-escalation trial design, aiming to evaluate the safety, tolerability, and preliminary efficacy of RY_SW01 cell injection in treating patients with active lupus nephritis.
The Phase II dose-expansion stage utilizes a randomized controlled trial design to further evaluate the safety and effectiveness of RY_SW01 cell injection.
The baseline treatment in this trial includes steroids in combination with immunosuppressants. Common immunosuppressants include mycophenolate mofetil, mycophenolate sodium, cyclophosphamide, azathioprine, and calcineurin inhibitors (cyclosporine or tacrolimus), which will be chosen by the researchers based on the patient's condition. During Phase II, the subject's existing baseline treatment regimen must not be increased or changed. If a subject's treatment is assessed as ineffective or intolerable and continuing the existing baseline treatment regimen will not yield better benefits, they may withdraw from the trial and then change their treatment plan or increase the dosage. Such subjects should be included in the effectiveness analysis.The trial will enroll active lupus nephritis patients aged ≥18 and ≤65 years, who must meet all inclusion criteria and none of the exclusion criteria.
Approximately 69-78 subjects are planned to be enrolled to undergo the dose-escalation and dose-expansion trials with RY_SW01 cell injection. About 9-18 evaluable subjects will be enrolled in the dose-escalation stage, and approximately 60 subjects in the dose-expansion stage.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ning Wei
- Phone Number: 15852926678
- Email: weining@rybiotech.cn
Study Contact Backup
- Name: Jing Wang
- Phone Number: 025-86162919
- Email: wangjing@rybiotech.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- the Affiliated Drum Tower Hospital, Medical School, Nanjing University
-
Contact:
- Lingyun Sun
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign an informed consent form.
- Male or female aged ≥18 and ≤65 years.
- Medical history indicating the fulfillment of at least 4 out of the 11 SLE classification criteria recommended by the American College of Rheumatology (ACR) in 1997, with a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of ≥6.
- Previous receipt of induction therapy (combination of steroids with immunosuppressants, biologics, or two or more treatments), as determined by the investigator, and the participant demonstrated intolerance to or lack of response to this treatment.
- Confirmed diagnosis of class III or class IV lupus nephritis according to the ISN/RPS classification criteria (Class III(A), Class III(A+C), Class IV(A), or Class IV(A+C)), with the possibility of being combined with Class V or isolated Class V (including activity and chronicity indices).
- Laboratory examination showing a urinary protein-to-creatinine ratio (UPCR) > 1000 mg/g or 100 mg/mmol or > 1.0.
- During the trial and for at least 1 year after injection administration, the participant has no plans for pregnancy and voluntarily agrees to use effective contraception with their partner (see Appendix 1) and has no plans for sperm or egg donation.
Exclusion Criteria:
- Severe liver dysfunction with any of the following abnormalities: total bilirubin > 2 times the upper limit of normal (ULN); ALT or AST > 2 times the ULN.
- Severe kidney dysfunction with eGFR < 30 mL/min/1.73m² or serum creatinine > 265.2 µmol/L.
- Kidney biopsy pathology indicating ≥50% glomerulosclerosis.
- Blood system abnormalities with any of the following abnormalities: white blood cell count < 2000/µL (2×10^9/L), hemoglobin < 6g/dL (60g/L), platelet count < 30000/µL (30×10^9/L), neutrophils < 1000/µL (1×10^9/L).
Severe and uncontrolled cardiovascular diseases, neurological disorders, pulmonary diseases (including obstructive lung disease and interstitial lung disease), liver diseases, endocrine disorders (including uncontrolled diabetes), and gastrointestinal diseases, including but not limited to:
- Patients with uncontrolled severe hypertension (≥160/100 mmHg).
- Patients with uncorrected heart failure or severe heart dysfunction (NYHA class ≥III).
- Patients with a history of myocardial infarction within the previous 6 months or meet the diagnostic criteria for acute myocardial infarction at screening.
- Patients with a history of acute stroke within the previous 6 months or at risk of acute cerebrovascular events at screening.
- Patients with a history of severe pulmonary hypertension.
- Patients with severe arrhythmias (e.g., rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia).
- Patients with a history of IgA deficiency (IgA < 10 mg/dL).
- Patients with other autoimmune diseases except for SLE, including dermatomyositis/polymyositis, mixed connective tissue disease, systemic sclerosis, rheumatoid arthritis, etc., should be excluded. However, patients with secondary Sjögren's syndrome are allowed to participate in this trial.
- Received live vaccines or attenuated live vaccines within the previous 12 weeks or expect to receive/require live vaccines during the trial.
- Underwent plasmapheresis or immunoadsorption therapy within the previous 24 weeks or received intravenous immunoglobulin (IVIG) therapy within the previous 4 weeks.
- Used other investigational drugs within the previous 12 weeks.
Tested positive for human immunodeficiency virus antibodies (anti-HIV-Ab) during screening, active syphilis, active hepatitis C (positive for hepatitis C antibodies, and HCV-RNA higher than the lower limit of detection), or positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA (HBV-DNA ≥500 IU/ml).
History of severe active or recurrent bacterial, viral, fungal, parasitic, or other infections during the screening period.
- History of malignant tumors within the past 5 years, including solid tumors, hematological malignancies, or in situ cancers (except for surgically removed or cured basal cell carcinoma of the skin).
- Underwent any major surgery within the previous 12 weeks or anticipated to undergo major surgery during the trial, which is considered to pose an unacceptable risk to the participant by the investigator.
Intolerance or contraindication to the treatment protocol of this trial, including any of the following conditions:
- History of allergies to allogeneic mesenchymal stem cells or excipients (including human albumin).
- Intolerance or contraindication to oral or intravenous corticosteroids.
- Absence of peripheral venous access.
- Pregnant or lactating women.
Within the previous 12 months or during the screening period, there is evidence of smoking, alcohol misuse, or drug abuse, defined as follows:
- Smoking defined as an average daily smoking of ≥5 cigarettes within the previous 3 months.
- Alcohol misuse defined as consuming more than 14 units of alcohol per week within the previous 3 months (1 unit of alcohol = 350 ml of beer, or 45 ml of spirits, or 150 ml of wine).
- Drug abuse defined as a positive result in urine drug screening or having a history of drug abuse.
- Participants judged by the investigator as not suitable for participation in this trial will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RY_SW01 group 1 does 1 RY_SW01 cell injection
Receive the best basic treatment and one million cells per kilogram of body weight
|
Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
Other Names:
Drugs for LN treatment
Other Names:
|
Experimental: RY_SW01 group 2 does 2 RY_SW01 cell injection
Receive the best basic treatment and two million cells per kilogram of body weight
|
Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
Other Names:
Drugs for LN treatment
Other Names:
|
Other: control group
Receive the best basic treatment
|
Drugs for LN treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of Adverse Events
Time Frame: Within 24 week
|
Within 24 week
|
Proportion of patients achieving a primary renal efficacy response (PERR)
Time Frame: 24week
|
24week
|
Proportion of patients achieving a complete response (CR)
Time Frame: 24week
|
24week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events and severe adverse events
Time Frame: within 24 weeks
|
within 24 weeks
|
|
Proportion of patients achieving primary renal efficacy response (PERR)
Time Frame: 12 week
|
12 week
|
|
Proportion of patients achieving primary renalcomplete response (CR)
Time Frame: 12 week
|
12 week
|
|
Changes in urine protein/creatinine ratio (UPCR) relative to baseline
Time Frame: 12 week
|
12 week
|
|
The proportion of patients reduced dosage of basic treatment drugs
Time Frame: 24week
|
24week
|
|
the proportion of Treg cell subset
Time Frame: 24 week
|
24 week
|
|
Changes in eGFR(estimated glomerular filtration rate)relative to baseline
Time Frame: 12 week
|
12 week
|
|
Changes in SLEDAI-2000(The Systemic Lupus Erythematosus Disease Activity Index 2000) ralative to baseline
Time Frame: 24 week
|
24 week
|
|
Changes in PGA(Physician Global Assessment) ralative to baseline
Time Frame: 24 week
|
24 week
|
|
Changes in SF-36 (Short-form 36 Questionnaire) ralative to baseline
Time Frame: 24 week
|
24 week
|
|
Serum biomarkers of antibody
Time Frame: Within 24 weeks
|
ANA,nti-dsDNA antibody
|
Within 24 weeks
|
Serum biomarkers
Time Frame: Within 24 weeks
|
C3,C4
|
Within 24 weeks
|
Serum biomarkers of cytokins
Time Frame: Within 24 weeks
|
TGF-β,IFN-γ,IL-6,IgG,CXCL10
|
Within 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sun Lingyun, the Affiliated Drum Tower Hospital, Medical School, Nanjing University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Kidney Diseases
- Urologic Diseases
- Connective Tissue Diseases
- Glomerulonephritis
- Lupus Erythematosus, Systemic
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Nephritis
- Lupus Nephritis
- Physiological Effects of Drugs
- Immunologic Factors
- Immunosuppressive Agents
Other Study ID Numbers
- RYSW202201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Nephritis
-
Imperial College LondonKarolinska Institutet; Ohio State University; Dutch Working Party on Systemic... and other collaboratorsTerminatedSystemic Lupus Erythematosus, Lupus NephritisUnited Kingdom
-
Sun Yat-sen UniversityCompleted
-
Peking UniversityCompleted
-
University Hospital, GrenobleInstitut de Biologie Structurale GrenobleCompletedSystemic Lupus Erythematosus NephritisFrance
-
Peking Union Medical College HospitalUnknownNephritis, LupusChina
-
Artiva Biotherapeutics, Inc.RecruitingLupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIUnited States
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIGermany
-
Minia UniversityNot yet recruitingmfERG in Lupus NephritisEgypt
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IVUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedLupus Nephritis | Systemic Lupus Erythematosus (SLE)France
Clinical Trials on RY_SW01 cell injection
-
Jiangsu Renocell Biotech CompanyThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...Recruiting
-
Royan InstituteCompletedBone CystIran, Islamic Republic of
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Royan InstituteCompletedNonunion FracturesIran, Islamic Republic of
-
Peking UniversityNot yet recruiting
-
Texas Plastic SurgeryUnknown
-
Royan InstituteCompletedLeg Length InequalityIran, Islamic Republic of
-
Beijing Boren HospitalTerminatedAdvanced Solid Tumor | Relapsed/Refractory LymphomaChina
-
Imbioray (Hangzhou) Biomedicine Co., Ltd.The First Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Imbioray (Hangzhou) Biomedicine Co., Ltd.Recruiting